The bioavailability of oral CBD formulations is very low, with some sources citing a percentage as low as 6%. This means that a meager 6% of CBD is available for use by the body when CBD is ingested through oral routes such as tablets and capsules.
Oral formulations are the preferred drug delivery route because of their ease of use and cost-effectiveness. With CBD (as well as other therapeutic cannabinoids) going mainstream, the inherent setbacks affecting the effective delivery of CBD must be addressed.
VESIsorb is a drug delivery system that enhances the bioavailability of lipophilic compounds (such as CBD) through self-emulsification.
Cannabis producers are embracing different technologies to improve the bioavailability of CBD. Theralogix recently launched a broad spectrum CBD-Beta Caryophyllene product that uses VESIsorb to enhance absorption- Therahemp.
VESIsorb Increases CBD Bioavailability by 440%
A 2019 study that was published in Molecules compared the pharmacokinetics of VESIsorb enhanced CBD to that of CBD in MCT. The study included 16 participants who were offered either of the two oral formulations of CBD. The German researchers found that VESIsorb increased the bioavailability of CBD in blood by 440% and the total absorption of CBD in 24 hours increased by 285%. Additionally, the peak level of CBD in the VESIsorb group occurred at 1 hour while the same happened in the control group after 3hours.
Chief Science Officer of Theralogix, Dr. Mark Ratner explains:
“The precise composition of VESIsorb can vary depending on the API and application, however, it is a lipid-based formulation that self-assembles in an aqueous environment into a colloidal delivery system. This colloidal solubilization improves the transport of fat-soluble APIs such as CoQ10, vitamin D – and cannabinoids – through the aqueous phase of the GI-lumen to the absorptive epithelium, significantly improving bioavailability.”
Therahemp contains 20mg of CBD and 8mg of Beta-Caryophyllene. The NSF international Hemp/ CBD certification program recommends 20mg as the standard “dose limit” for CBD, Dr. Ratner reports.
Beta-Caryophyllene is a CB2 Receptor Agonist
In spite of many terpenes showing bioactivity, beta caryophyllene is the only terpene that has shown direct action at endocannabinoid receptors. Research has shown that beta caryophyllene is an agonist at the CB2 receptor, just like CBD. CB2 receptors are mainly found in immune cells and when activated they downregulate the immune response. This can be harnessed in the treatment of autoimmune conditions.
Researchers are looking into the therapeutic potential of CBD including the treatment of mood disorders, seizures, autoimmune conditions, and chronic pain. VESIsorb is proving to be a panacea for the bioavailability challenge that has stalled the uptake of cannabinoid-based therapies.